Interpreting trials on renal replacement therapy initiation: beware of methodologic issues
Critical Care volume 24, Article number: 240 (2020)
No large-scale randomized controlled trial (RCT) on the initiation strategy for renal replacement therapy (RRT) in critically ill patients with acute kidney injury (AKI) was available for years. Expert opinion  and consensus conferences  recommend a conservative approach with RRT initiated only when life-threatening complications (hyperkalemia, intractable acidosis, or diuretic-unresponsive pulmonary edema) are present. However, RRT is often initiated earlier based mainly on amount of hourly urine output and/or urea nitrogen or serum creatinine concentration  even in the absence of the abovementioned complications. This attitude is based on the putative deleterious effects of high levels of nitrogen waste products and of hypothetical ill-effects of mediators of inflammation or other elusive factors. This approach assumes that theoretical advantages of early RRT surpass its actual risks, including catheter-related problems, hypotension, complications of anticoagulation, and the risk that treatment may actually prolong the course of AKI.
For many years, only small RCTs  and observational studies of the timing of RRT  were available. Observational studies compared patients with AKI who received early RRT with those who received it later but did not account for patients who either recovered or died without receiving RRT . These patients who did not require RRT during AKI were shown to have a good prognosis  and not including them biases analyses comparing early to delayed strategies. Not surprisingly, most meta-analyses concluded that “early” RRT was associated with better survival .
Only RCTs comparing strategies for RRT initiation could solve the conundrum  (Fig. 1). Patients should not be simply randomized to “early” or “late” RRT but rather to an early strategy in which patients with severe AKI receive RRT shortly after the diagnosis is made or to a delayed strategy in which RRT is postponed until specific criteria for initiation are met. One single-center  and two multicenter [10, 11] RCTs utilized such protocols. Their conclusions differed: the former reported lower mortality with the early strategy but the two others did not show any mortality difference. Our purpose is not to delineate which study is correct, although the former received several criticisms . A recent individual patient-data meta-analysis of RCTs included more than 1500 patients and showed that mortality was not affected by the strategy of RRT initiation and that 42% of patients allocated to a delayed strategy did not receive RRT .
A methodological distortion would analyze patients based on post hoc groups by splitting the delayed strategy in two artificial subgroups: those who did or did not ultimately receive RRT. Such analyses will likely find that patients in the delayed arms who ultimately received RRT had worse outcomes than those who received early RRT. This falls back into the methodological flaws of prior observational studies. At the point of randomization, patients allocated to either the early or delayed strategies form a heterogeneous population. Some patients rapidly recover or die for reasons unrelated to their AKI and even less so to the assigned RRT strategy. Some have a more prolonged course during which they may suffer from complications unrelated to AKI. A delayed strategy allows time for clarifying the medical situation of individual patients. Thus, three disparate populations with differing mortality risk profiles may become apparent: those who recover kidney function without reaching specified objective criteria for RRT, those who die of non-renal complications prior to RRT initiation, and those with prolonged AKI, who ultimately meet the pre-specified criteria for RRT. The pseudo group of patients randomized to delayed RRT who ultimately receive RRT per protocol have time to develop complications in the ICU either because of the severity of their initial disease or because of additional events.
This flaw can be illustrated using two theoretical examples. First, a patient with a urinary tract infection and septic shock has KDIGO stage 3 AKI. Their hemodynamic condition rapidly improves, but oliguria persists for several hours, and they are allocated to an early RRT strategy and receive RRT rapidly. Their diuresis resumes within 24 h, and kidney function improves making further RRT unnecessary. They are alive after 60 days. Had this patient been allocated to the delayed group, it is unlikely that they would have received RRT. In addition, survival is not the result of “early” RRT initiation. In a second example, a patient with severe atherosclerosis has abdominal sepsis with septic shock. Anuria develops, and they are randomized to a “delayed RRT strategy”. At randomization they have no severe metabolic complication. After 2 days, their sepsis worsens and they develop hemodynamic instability requiring vasopressor administration. Persistence of anuria and development of hyperkalemia mandate RRT. Subsequently, they develops massive hemiplegia. A CT-scan shows cerebral infarction in the middle cerebral artery territory with massive edema which is rapidly complicated by cerebral herniation. Brain death ensues. These complications cannot reasonably be attributed to the strategy of delayed RRT initiation.
Subgroup analysis based on post-randomization disease trajectory and not on baseline variables is flawed. Indeed, this comparison is subject to two kinds of bias . First, indication bias: by definition, patients who finally received RRT in the “delayed group” were those who needed it because of the unfavorable evolution of their AKI and overall illness. This results in time-varying confounding. Second, immortal time bias: since patients who received RRT in the delayed strategy did not receive it per randomized allocation, but as a result of follow-up.
Taken together there is a logical coherence between methodological and pragmatic arguments to demonstrate without any ambiguity that timing of RRT does not affect prognosis and that artificially creating groups based on results is a trap that the wise clinician should avoid.
Convincing clinicians that “less may be more” may be difficult (even if this leads to much less use of RRT and substantial savings). As stated by JPA Ioannidis : “Yet, how likely is it that physicians will design studies whose results may threaten their jobs by suggesting that less procedures, testing, interventions are needed … … Is EBM doomed to be heartily accepted only when it leads to more medicine, even if this means less health?”
Availability of data and materials
Acute kidney injury
Randomized controlled trial
Renal replacement therapy
Intensive care unit
Gibney N, Hoste E, Burdmann EA, Bunchman T, Kher V, Viswanathan R, et al. Timing of initiation and discontinuation of renal replacement therapy in AKI: unanswered key questions. Clin J Am Soc Nephrol. 2008;3:876–80.
Brochard L, Abroug F, Brenner M, Broccard AF, Danner RL, Ferrer M, et al. An official ATS/ERS/ESICM/SCCM/SRLF statement: prevention and management of acute renal failure in the ICU patient: an international consensus conference in intensive care medicine. Am J Respir Crit Care Med. 2010;181:1128–55.
Legrand M, Darmon M, Joannidis M, Payen D. Management of renal replacement therapy in ICU patients: an international survey. Intensive Care Med. 2013;39:101–8.
Bouman CSC, Oudemans-Van Straaten HM, Tijssen JGP, Zandstra DF, Kesecioglu J. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med. 2002;30:2205–11.
Kleinknecht D, Jungers P, Chanard J, Barbanel C, Ganeval D. Uremic and non-uremic complications in acute renal failure: evaluation of early and frequent dialysis on prognosis. Kidney Int. 1972;1:190–6.
Palevsky PM. Indications and timing of renal replacement therapy in acute kidney injury. Crit Care Med. 2008;36:S224–8.
Gaudry S, Ricard J-D, Leclaire C, Rafat C, Messika J, Bedet A, et al. Acute kidney injury in critical care: experience of a conservative strategy. J Crit Care. 2014;29:1022–7.
Karvellas CJ, Farhat MR, Sajjad I, Mogensen SS, Leung AA, Wald R, et al. A comparison of early versus late initiation of renal replacement therapy in critically ill patients with acute kidney injury: a systematic review and meta-analysis. Crit Care. 2011;15:R72.
Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstadt H, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA. 2016;315:2190–9.
Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med. 2016;375:122–33.
Barbar SD, Clere-Jehl R, Bourredjem A, Hernu R, Montini F, Bruyère R, et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. N Engl J Med. 2018;379:1431–42.
Lameire N, Vanmassenhove J. Timing of dialysis in sepsis and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2018;198:4–5.
Gaudry S, Hajage D, Benichou N, Chaibi K, Barbar S, Zarbock A, et al. Delayed versus early initiation of renal replacement therapy for severe acute kidney injury: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2020;395(10235):1506–15.
Gershon AS, Jafarzadeh SR, Wilson KC, Walkey AJ. Clinical knowledge from observational studies. Everything you wanted to know but were afraid to ask. Am J Respir Crit Care Med. 2018;198:859–67.
Ioannidis JPA. Evidence-based medicine has been hijacked: a report to David Sackett. J Clin Epidemiol. 2016;73:82–6.
Ethics approval and consent to participate
Consent for publication
Dr. Palevsky reports receiving consulting fees from Baxter. SG and DD declare no competing interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Gaudry, S., Palevsky, P.M. & Dreyfuss, D. Interpreting trials on renal replacement therapy initiation: beware of methodologic issues. Crit Care 24, 240 (2020). https://doi.org/10.1186/s13054-020-02961-z